Seeking Alpha

SciClone Pharmaceuticals (SCLN) says it will be restating financial statements for fiscal Q1,...

SciClone Pharmaceuticals (SCLN) says it will be restating financial statements for fiscal Q1, Q2, Q3 of 2011 as well as Q2 and Q3 in 2012 to account for accounting errors within its NovaMed subsidiary in China. The restatement primarily relates to accounting errors over the timing of Pfizer product revenue recognition and the recognition of product return reserves for its Aggrastat anticoagulant drug. SCLN acquired NovaMed in April 2011. Shares -6% AH.
Comments (1)
  • Zachary Schenk
    , contributor
    Comments (78) | Send Message
     
    Revenue will increase by 3mill in 2012 and decrease in 2011 by 1 mill for a net 2 mill increase ... But goes down AH?
    22 Feb 2013, 07:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector